Galera Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Net Income	149.05	-18.96	-59.08	-62.22	-80.53	Upgrade
Depreciation & Amortization	-	0.02	0.26	0.11	0.78	Upgrade
Loss (Gain) From Sale of Assets	-3.5	0.05	-0.07	-	-	Upgrade
Asset Writedown & Restructuring Costs	-	6.98	-	-	-	Upgrade
Stock-Based Compensation	0.41	2.55	5.56	7.16	7.23	Upgrade
Other Operating Activities	-151.34	-0.66	11.41	11.5	7.19	Upgrade
Change in Accounts Payable	-1.01	-1.42	-2.21	-1.46	-0.1	Upgrade
Change in Other Net Operating Assets	0.35	-0.71	-0.72	1.48	-2.53	Upgrade
Operating Cash Flow	-6.05	-12.15	-44.85	-43.43	-67.96	Upgrade
Capital Expenditures	-	-	-0.06	-0.03	-0.28	Upgrade
Sale of Property, Plant & Equipment	3.5	0	-	-	-	Upgrade
Cash Acquisitions	-	-0.05	-	-	-	Upgrade
Investment in Securities	-	-	27.35	24.02	5.52	Upgrade
Investing Cash Flow	3.5	-0.05	27.29	23.99	5.24	Upgrade
Long-Term Debt Issued	-	-	-	-	57.5	Upgrade
Net Debt Issued (Repaid)	-	-	-	-	57.5	Upgrade
Issuance of Common Stock	0.64	2.22	31.5	3.89	9.21	Upgrade
Financing Cash Flow	0.64	2.22	31.5	3.89	66.71	Upgrade
Net Cash Flow	-1.91	-9.97	13.94	-15.54	3.99	Upgrade
Free Cash Flow	-6.05	-12.15	-44.91	-43.45	-68.24	Upgrade
Free Cash Flow Per Share	-0.06	-0.22	-1.01	-1.60	-2.65	Upgrade
Levered Free Cash Flow	-3.4	-7.78	-35.66	-32.1	-44.7	Upgrade
Unlevered Free Cash Flow	-3.4	-7.78	-28.53	-24.87	-40.2	Upgrade
Change in Working Capital	-0.67	-2.13	-2.93	0.02	-2.63	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.